Inspection Record

Triad Rx, Inc. — FDA 483 Findings

US FDAInspected 2017-09-19Published 2024-01-17 9 findingsAseptic processing and sterility assuranceEnvironmental monitoringEquipment and facility

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Equipment, materials, and/or supplies are not disinfected prior to entering the aseptic processing areas.

2Aseptic processing and sterility assurance

Inadequately or un-protected product intended to be sterile was observed to be exposed to lower than ISO 5 quality air.

3Aseptic processing and sterility assurance

Cleaning pads or wipes used in the ISO 5 area are not sterile.

4Aseptic processing and sterility assurance

Personnel were observed conducting aseptic manipulations or placing equipment/supplies in an area that blocked the movement of first pass air around an open unit, whether before or after it is filled with sterile product.

5Aseptic processing and sterility assurance

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

6Environmental monitoring

The use of sporicidal agents in the cleanrooms and/or ISO 5 area is inadequate or infrequent.

7Aseptic processing and sterility assurance

Personnel engaged in aseptic processing were observed with exposed hands, wrists, legs, hair, or mouth.

8Equipment and facility

The ISO-classified areas have difficult to clean, particle-generating, or visibly dirty equipment or surfaces.

9Aseptic processing and sterility assurance

Personnel were observed touching equipment or other surfaces located outside ofthe ISO 5 area with gloved hands and then proceeding with aseptic processing without changing or sanitizing gloves.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Triad Rx, Inc. company profile — full history US FDA documents, 2024 Go to Findings search